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The need for better anti-complement drugs in certain 
complement mediated diseases and disease states remains 
pressing (1). The recent data published by Ueda et al. (2), 
appears to offer another highly effective solution to target 
complement activation in atypical haemolytic uraemic 
syndrome (aHUS). AHUS is a primary thrombotic 
microangiopathy (TMA), clinically characterized by acute 
kidney injury, microangiopathic haemolytic anaemia, and 
thrombocytopenia (1). AHUS, along with paroxysmal 
nocturnal haemoglobinuria (PNH) and C3 glomerulopathy 
(C3G), are archetypal complement mediated diseases. With 
aHUS and PNH being treated, on the whole, through use 
of the C5 functional blocking antibody therapy eculizumab 
(SolirisTM) (1,3). Despite the clear role of complement in 
C3G, its successful treatment using eculizumab has had 
mixed success (1).
In the most comprehensive analysis to date, >600 rare 
variants in 10 complement genes have been identified in 
over 3,000 aHUS patients (identified in 6 reference centres 
including our own) (4), the majority of these changes are 
found in the alternative pathway of complement activation 
(Figure 1), particularly its regulators, factor H (FH) and 
membrane cofactor protein (MCP, CD46). Indeed, the first 
described mouse model of aHUS used a genetic deletion 
of the last 5 SCRs of FH, i.e., FH delta CCP16-20, (a 
change not seen in man), to demonstrate that the carboxy 
terminus of FH is essential to prevent aHUS-like disease (5) 
and confirmed that surface localisation of FH is critical to 
prevent aHUS. The relative success of that model, with 
respect to replication of the pathological features of the 
human disease in mouse has led to several attempts to 
generate even more realistic models of aHUS based on 
single amino acid variations. One such model is the FH 
W1206R or FHR/R model (6). It is based on a C terminal 
FH mutation found in aHUS patients that in homozygous 
mice, allows uncontrolled C3b deposition on host tissue 
leading to renal failure, stroke and retinopathy (2,6). The 
resulting model appears to represent an aggressive TMA 
with occlusive microvascular and macrovascular disease. 
It is worth noting that only a 5th of aHUS patients display 
extrarenal complications while retinal involvement and 
stoke are rare events in aHUS patients (7). In the FHR/R 
model, approaching one third of the tested mice displayed 
symptoms of stroke and ischemic retinopathy. The onset of 
organ thrombosis and renal injury occurred within the first 
week of life, with sudden death being observed on numerous 
occasions, culminating in just under half of the FHR/R 
animals (but none of the heterozygous variant animals) 
being removed from the study by 30 weeks post-partum (6). 
Arguably, this provides an ideal and stringent test for 
therapeutics destined to reverse the effects of rampant 
uncontrolled complement activation at the cell surface. 
Furthermore, as mice develop disease from 3–4 weeks of 
age, with FHR/R mice being smaller and thinner than FHR/
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Figure 1 An AP focused overview of the complement system. Activation of complement (C) can occur via three pathways—the classical, 
lectin, and AP, depending on the trigger, with all resulting in the cleavage of the pivotal molecule, C3 into C3a and C3b by C3 convertases. 
The AP is perpetually and slowly active through a mechanism known as tick-over i.e., the spontaneous hydrolysis of C3. This C3(H2O) 
species can form an initial fluid phase C3 convertase upon association with FB that is cleaved by the proteolytic enzyme FD, generating 
C3(H2O)Bb and Ba. C3(H2O)Bb can now interact with C3 to generate C3b and C3a within the amplification loop. Bound C3b on surfaces 
forms a platform for FB binding, creating C3bB, which is rapidly cleaved by FD to C3bBb (a new C3 convertase) which can readily bind 
properdin (P), which stabilises the newly formed convertase (C3bBbP). The AP can be initiated by properdin as this molecule recognizes 
target surfaces (such as apoptotic bodies, cells) and subsequently recruits C3b and FB to form stabilized C3 convertases. As the classical and 
lectin pathway also generate C3b, the amplification loop within the AP is incredibly important to propagate the activity of complement per 
se. As sufficient saturation is reached C3b can attach to preformed C3 convertase complexes to form C5 convertases that allow the terminal 
pathway of complement to proceed i.e. C5 is cleaved into C5a and C5b. C5b then recruits C6, C7, C8, and up to thirteen C9 molecules to 
form the membrane attack complex (MAC; C5b-9) which can punch holes in cell membranes. Naturally, all this ‘fire power’ needs control 
and so many regulators of complement exist (selection noted in grey boxes) with Factor H and Factor I being critical for control of the AP. 
The site of action of eculizumab and anti-properdin are also illustrated. AP, alternative pathway; FB, factor B; FD, factor D.
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W or FHW/W littermates, this is a relatively cost-effective 
model to run compared to the FH knockout model of C3G 
(for instance).
Thus, the clear success of anti-properdin therapy by 
Udea et al. (2), with complete blockade of properdin 
function and prevention of sudden death and reduction of 
disease markers over the 2 months analysed in the FHR/R 
mouse is a significant finding. These findings clearly echoed 
results from the backcross of the FHR/R mice with properdin 
knockout (P-/-; Pflox/flox crossed with EIIa-Cre) mice carried 
out in the same study which demonstrated a highly 
important role of properdin in fostering the complement 
activation that drives the pathological outcomes of TMA. 
This is logical based on the central role that properdin plays 
in cross-talk between platelets and neutrophils, driving 
another important feedback loop of activation of each cell 
type which drives thrombo-inflammation (8).
The AP is a uniquely important part of the complement 
system (9) and interacts with the other activation pathways 
to amplify the innate and acquired immune response (10). 
Indeed, too many, it is this amplification or feedback loop 
potential that defines the AP. For instance, the AP has 
been shown to account for approximately 80% of terminal 
pathway activation when complement activity is initiated 
by either the classical or lectin pathways. Indeed, properdin 
inhibitors have been suggested to be approximately four 
fold more effective than C5 inhibitors in preventing 
sheep red blood cell lysis in the presence of C terminal 
FH perturbation (8).Thus, the targeting of properdin, an 
important positive regulator of the AP (8) (see Figure 1), 
has several obvious/attractive points. Primarily properdin 
is essential for effective AP function although some AP 
function can occur in the absence of properdin (11) and will 
leave the Classical and Lectin activation pathways intact. 
Properdin is produced mainly by leucocyte populations (as 
well as adipocytes and stimulated endothelial cells) and is 
found in the circulation at relatively low concentrations of 
4–25 µg/mL (about 5 fold less than C5, at ~75 µg/mL) (12), 
so one of the potential advantages that anti-properdin 
treatment may offer compared to eculizumab is the need for 
a lower dose of the antibody to deplete/block the protein. 
However, that remains to be seen based on the data from 
the mouse model, i.e., platelet levels and haemoglobin 
were only fully stabilised when the 2 mg per mouse per 
week dose (roughly between 150–100 mg/Kg across the 
study) was used. This is a markedly higher dose than that 
currently used for eculizumab, at any phase of treatment (3) 
or 3 fold the effective dose for use of BB5.1, a murine 
ortholog of eculizumab (13). While C5 expression, which is 
produced predominately in the liver, can increase in response 
to inflammation, arguably local properdin levels can and do 
rise more rapidly in response to inflammatory stimuli and, 
in the case of endothelial cells, laminar shear stress (12). The 
conditions that provoke TMA are likely to provoke a rapid 
increased in local properdin expression levels (8). This may 
explain the need for use of high dose of anti-properdin to 
completely block properdin function in the FHR/R model. 
Similar doses were used in other studies using different 
anti-properdin blocking antibodies to prevent complement 
mediated disease (14) not initiated by AP activation. In short, 
these murine models do suggest the need for a high dosing 
strategy to maintain properdin deficiency.
Of course, we at the National Renal Complement 
Therapeutics Centre (NRCTC) of the United Kingdom 
were one of the first to recognise that eculizumab (SolirisTM) 
through the complete blockade of the terminal pathway 
of complement (Figure 1) is a highly effective treatment 
in many patients with aHUS (15). However, we also 
accept that eculizumab is not a panacea (1) in this disease 
and has had mixed success in the treatment of C3G. 
Furthermore, due to the high cost of eculizumab, plasma 
exchange remains the only affordable treatment in many 
parts of the world. One of the major risk factors with the 
use of any anti-complement drug is the increased risk 
of infection. Use of eculizumab essentially completely 
switches off two important components of our immune 
system, i.e., generation of membrane attack complex and 
C5 a naphylatoxin. The loss of these effector mechanisms 
leaves patients treated with the drug highly susceptible 
to infections that can cause meningitis, requiring prior 
vaccination and, in certain treatment centres including 
the UK, prophylactic antibiotics before treatment can 
proceed (1,3). So would properdin depletion be any safer? 
This is arguable, extrapolating from the role of properdin 
in promoting the amplification loop of the AP and how 
that translates into terminal pathway activation (8), 
its perhaps not surprising that properdin deficiency is 
associated with a markedly increased (250 fold) risk of 
meningococcal infection, particularly to serotypes such as 
W-135 and Y (16) compared with complement sufficient 
individuals. Furthermore, properdin deficiency is estimated 
to increase the rate of mortality during infection to 33% in 
comparison with rates of 5–7% for individuals with terminal 
complement component deficiencies or are complement-
sufficient (16). Studies in animal models with properdin 
deficiency also highlight that properdin is crucial for 
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robust host defence against certain, but not all, microbial 
pathogens (17). This is logical in that loss of properdin 
will blunt activation of the terminal pathway regardless of 
the initiation pathway (14) as well as interfere with C3a/
C5a anaphylatoxin signalling and opsonisation which is 
important to both innate and adaptive cell activation/
responses. This deficit is balanced by the fact that anti-
properdin therapy, similar to other approaches targeting the 
AP (8,18), will allow a certain level of classical and lectin 
pathway mediated terminal pathway/anaphylatoxin activity 
to remain intact. Of course, it’s notable that concerns 
surrounding increased infectious risk have not prevented 
an anti-properdin therapy, CLG561, from reaching phase 
II clinical trials in the treatment of age-related macular 
degeneration (19). Overall, these data suggest that total 
blockade of properdin function (if achievable systemically) 
in the patient population will require considerations 
surrounding increased risk of infection that are broadly 
similar to C5 blockade. 
A further note of caution on this topic is that while 
preventative vaccination against meningitis is routine in 
the use of anti-complement drugs, it is important to also 
consider in patients with deregulated complement systems 
that an inefficient/or perturbed complement system may 
have significant detrimental effects on vaccine responses (10) 
i.e., protective vaccination in patients with rare variants in 
complement proteins may be significantly compromised and 
therefore less likely to provide the protection that would 
otherwise be expected. That sentiment is upheld by current 
patient data, i.e., patients on eculizumab still remain at 
high risk of meningococcal disease despite vaccination (20). 
However, there is evidence that vaccination against 
meningococcus can be effective in properdin deficient 
patients (16) and prophylactic use of penicillin can further 
reduce this risk (1). 
Over the last decade, we have successfully generated 
several unique recombinant mouse C3 molecules based on 
variants found in human C3 that associated with aHUS 
or C3G, with an aim to better understand how certain 
pathological variants in C3 associate with particular disease 
pathology. In doing so, we demonstrated that we could 
transfer functional changes from patients with aHUS to 
a mouse model (21). Mice with a single point mutation 
in C3, i.e., pC3.D1115N (gain-of-function, C3 GOF) 
on both gene copies of C3 rapidly develop aHUS with a 
pathology that is identical to the original patients described 
with the variant. Furthermore, our data also confirms that 
C5 deletion or blockage (using BB5.1) rescues mice from 
the disease phenotype (22) and therefore validates the 
model for testing of other anti-complement drugs (Smith-
Jackson et al., accepted subject to revision, JCI). However, 
in preliminary analysis using H4 (14), a properdin function 
blocking antibody, we saw little if any positive effects of 
using the treatment (Smith-Jackson et al., unpublished). 
While many reasons for this poor response in our aHUS 
model exist at this present time, it does potentially remind 
us that all pathological mechanisms in aHUS are not the 
same. Indeed, C3 variants may produce disease pathology 
which sits between aHUS and C3G. This has important 
implications as deletion of properdin in the FH knockout 
mouse (model of C3G) significantly exacerbated disease (23) 
as measured at 38 weeks. This was similar, if not, much 
more marked, in another model where mice succumbed to 
disease between 8–12 weeks in the presence of low levels 
of a mutant FH and FP deficiency compared to 12-month 
disease onset when just low FH was present (24). The 
reason for properdin deficiency not being protective in 
models of C3G remains largely uncertain as several studies 
demonstrated that deletion or blockade of properdin was 
protective in murine models of complement dependent 
disease (8) as would have been more readily predicted. It 
is likely that the difference between the Udea et al. model 
of aHUS and the C3G models could be related to the 
way properdin interacts with C3 at a cell surface (plus/
minus effects on FH binding/FH related protein function 
etc.) versus in the fluid phase and how that influences C5 
convertase generation. This raises questions about the use 
of anti-properdin drugs in certain kidney diseases or more 
precisely in patients with particular rare variants in C3 or 
FH or with particular C3/C5 convertase autoantibodies 
(C3 & C5 nephritic factors) that need detailed and careful 
examination (see Michels et al. for a comprehensive 
review) (17). Indeed, there may be a rational argument 
for use of combined therapy, with anti-properdin mAbs 
supplemented with use of FH module based therapies, such 
as TT30, mini-FH or HDM-FH (8,18) but this will require 
considerable detailed analysis to confirm. 
Unlike FH and C3, there does not appear to be any 
genetic/familial evidence for a role in properdin loss or 
gain-of-function in association with aHUS. Only two rare 
variants in properdin were reported in the 6 centres study (4) 
and a maximal of 5–6 missense changes (MAF <0.01; 
normal plasma properdin expression levels) have been 
found associated with aHUS (Prof. Santiago Rodriquez 
de Cordoba—personal communication). So, a direct role 
of properdin variants in the development of aHUS seems 
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unlikely and thus changes in other factors surrounding 
properdin function remain of primary focus in development 
of aHUS. These data may also hint that the role of 
properdin in TMA mediated disease is secondary to the 
initial complement activation and potentially links back to 
the prominent role of properdin in thrombo-inflammation.
Conclusions 
The study by Ueda et al. has clearly demonstrated an 
important role for properdin in aggressive TMA mediated 
disease. Thus, with many questions surrounding the 
long-term risks of eculizumab therapy and costs/dosing 
regimens remaining largely unresolved, the potential to 
use anti-properdin or other anti-complement drugs (25) 
needs to be explored. Based on the result of one animal 
model of aHUS, anti-properdin maybe a serious option 
but it does come with a few caveats at the moment. The 
fact that FHR/R mice do not just develop renal TMA but 
also develop systemic thrombophilia involving large 
blood vessels in the brain, liver, lung, spleen and kidney 
suggests some consideration is needed before findings in 
the FHR/R model are extrapolated to less aggressive TMA 
and other complement mediated diseases. Of course 
before use of anti-properdin in kidney disease, clinicians 
would need to be certain of pathophysiological basis 
of the glomerular diseases that they are faced with i.e., 
deregulation of surface complement activation (aHUS) or 
deregulation of systemic complement activation (C3GN, 
DDD, atypical post infectious glomerulonephritis). This 
remains a challenge although enormous progress has been 
made in standardisation and provision of complement 
analysis, biochemical, immunological and genetic; with 
the message that a comprehensive diagnostic approach 
remains critical for these patients. Once diagnosis is clear 
and the appropriate controls (vaccination/prophylactic 
antibiotic strategies in place) use of anti-properdin therapy 
for treatment of severe TMA/aHUS may have a prominent 
place in the clinical armoury.
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